Common Retatrutide Research Peptide Dosages Seen in Studies: Lab Overview
Common Retatrutide Research Peptide Dosages Seen in Studies: Lab Overview
Last Updated: March 19, 2026 | Reading Time: ~9 minutes
Important Disclaimer: This article summarizes dose ranges used in published clinical research studies for scientific reference purposes only. Palmetto Peptides sells retatrutide exclusively for in vitro laboratory research. This information is not intended to guide, recommend, or imply any dosing for human or veterinary use. Retatrutide is not FDA approved for any therapeutic application. Nothing here constitutes medical advice.
Why Researchers Reference Published Dose Data
When researchers design in vitro experiments or preclinical studies involving retatrutide, they often reference the dose ranges used in published clinical trials. This is standard practice across peptide research — understanding what concentrations have been studied in formal research contexts helps labs design relevant, meaningful experiments and correctly frame their findings in relationship to the broader literature.
This article documents the dose ranges from published Phase 1, Phase 2, and Phase 3 retatrutide studies for that purpose.
For the underlying mechanism behind these doses, see How Retatrutide Works: The Triple-Action Peptide Explained. For full trial results in context, see the Complete Guide to Retatrutide Research Peptide.
Phase 1 Studies: Initial Human Dosing
The first human exposure to retatrutide was described in two Phase 1 studies, one in healthy volunteers and one in people with type 2 diabetes.
The Phase 1b multiple-ascending dose trial (Urva et al., The Lancet, 2022) recruited adults with type 2 diabetes and tested retatrutide at ascending doses up to 12 mg per week over a 12-week period. This study established that the compound was well-tolerated at doses from approximately 0.5 mg up to 12 mg weekly, demonstrated the pharmacokinetic profile consistent with once-weekly dosing, and provided early evidence of weight reduction and glycemic improvements.
Key Phase 1 observations: - Pharmacokinetic half-life consistent with once-weekly dosing - Dose-dependent weight reduction observed over 12 weeks - Gastrointestinal adverse events were dose-dependent and manageable - Confirmed the compound moved forward into Phase 2 development
Phase 2 Obesity Trial Dose Groups
The landmark Phase 2 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity but without type 2 diabetes. This study used a factorial design with multiple starting doses and target maintenance doses.
Dose Groups and Starting Doses
| Target Dose | Starting Dose Option A | Starting Dose Option B |
|---|---|---|
| 1 mg | 1 mg (no escalation) | N/A |
| 4 mg | 2 mg (escalate to 4 mg) | 4 mg (start at target) |
| 8 mg | 2 mg (escalate to 8 mg) | 4 mg (escalate to 8 mg) |
| 12 mg | 2 mg (escalate to 12 mg) | N/A |
This design was chosen specifically to compare whether starting at 2 mg versus 4 mg affected tolerability on the way to higher maintenance doses. The lower 2 mg starting dose proved to partially mitigate gastrointestinal adverse events, consistent with gradual receptor up-regulation.
Phase 2 Obesity Trial: Dose-Response at 48 Weeks
| Dose | Mean Weight Change at 24 Weeks | Mean Weight Change at 48 Weeks |
|---|---|---|
| Placebo | -1.6% | -2.1% |
| 1 mg | -7.2% | -8.7% |
| 4 mg | -12.9% | -17.1% |
| 8 mg | -17.3% | -22.8% |
| 12 mg | -17.5% | -24.2% |
Source: Jastreboff AM et al., NEJM 2023. Data from a Phase 2 research trial. Not predictive of individual outcomes.
The dose-response relationship here is notable: higher doses produced greater weight reduction up to the 12 mg maximum, with a fairly steep slope between 1 mg and 8 mg before flattening somewhat between 8 mg and 12 mg.
Phase 2 Type 2 Diabetes Trial Dose Groups
The Phase 2 diabetes trial (Rosenstock et al., The Lancet, 2023) enrolled 281 adults with type 2 diabetes and a BMI of 25 to 50 kg/m². In addition to placebo and retatrutide arms, this trial included a dulaglutide 1.5 mg active comparator arm for context.
Dose Groups
| Arm | Dose | Comparator |
|---|---|---|
| Placebo | N/A | Yes |
| Retatrutide | 0.5 mg weekly | No |
| Retatrutide | 4 mg weekly | No |
| Retatrutide | 8 mg weekly | No |
| Retatrutide | 12 mg weekly | No |
| Dulaglutide | 1.5 mg weekly | Yes (active) |
This trial ran for 36 weeks and used co-primary endpoints of HbA1c reduction and body weight change.
Phase 2 Diabetes Trial: Key Outcomes by Dose (36 Weeks)
| Dose | Mean HbA1c Change | Mean Weight Change | % Achieving HbA1c ≤6.5% |
|---|---|---|---|
| Placebo | -0.5% | -3.0% | ~12% |
| Dulaglutide 1.5 mg | -1.6% | -2.5% | ~30% |
| Retatrutide 4 mg | -2.0% | -13.3% | ~76% |
| Retatrutide 8 mg | -2.2% | -16.8% | ~80% |
| Retatrutide 12 mg | -2.2% | -16.9% | ~82% |
Source: Rosenstock J et al., The Lancet 2023. Phase 2 data, not for clinical extrapolation.
The performance relative to dulaglutide (itself an approved and effective GLP-1 receptor agonist) is notable in this context, particularly the rate of HbA1c normalization at 76 to 82% versus approximately 30% with dulaglutide.
Phase 2 Liver Fat Substudy Doses
The MASLD liver fat substudy (Sanyal et al., Nature Medicine 2024) used the same dose arms as the main obesity trial: 1 mg, 4 mg, 8 mg, and 12 mg weekly, plus placebo, over 48 weeks (with the primary endpoint assessed at 24 weeks).
Liver Fat Reduction by Dose (24 Weeks)
| Dose | Mean Relative Liver Fat Change at 24 Weeks |
|---|---|
| Placebo | +0.3% |
| 1 mg | -42.9% |
| 4 mg | -57.0% |
| 8 mg | -81.4% |
| 12 mg | -82.4% |
Source: Sanyal AJ et al., Nature Medicine 2024.
Phase 3 TRIUMPH Program: What Is Being Studied
The Phase 3 TRIUMPH trials are using higher doses than the earlier Phase 2 exploratory work, typically evaluating the two highest doses (8 mg and 12 mg) that showed the greatest efficacy signal in Phase 2. Full dose data from TRIUMPH trials is still emerging as of early 2026.
The TRIUMPH-4 trial (osteoarthritis), which reported positive topline results in 2025, evaluated the safety and efficacy of the two highest investigational doses of retatrutide in adults with obesity and knee osteoarthritis.
Considerations for Labs Referencing This Data
Researchers designing experiments that reference clinical trial doses should consider:
Subcutaneous administration: All Phase 2 and Phase 3 clinical doses were administered subcutaneously, once weekly. For in vitro cell culture or other non-animal experimental contexts, the relationship between administered dose in a clinical trial and the relevant concentration for your assay system is determined by your specific experimental design, not by the published clinical dose directly.
Dose escalation: Published studies consistently showed better tolerability with slower escalation to maintenance doses. For any in vitro or mechanistic work that draws on this dose-response data as context, acknowledging the escalation design is important for accurate citation.
Ongoing trials: Phase 3 data will expand the published dose-response understanding considerably over the next two to three years. Dose recommendations for research study context may evolve as this data is published.
Summary
Published retatrutide clinical studies evaluated doses of 0.5 mg, 1 mg, 4 mg, 8 mg, and 12 mg administered subcutaneously once weekly. The 12 mg dose produced the greatest efficacy in both the obesity (24.2% mean weight reduction at 48 weeks) and type 2 diabetes (82% achieving HbA1c normalization at 36 weeks) trials. Dose escalation from a 2 mg starting dose improved gastrointestinal tolerability compared to starting at 4 mg. Phase 3 trials are currently evaluating the 8 mg and 12 mg doses across multiple therapeutic research areas.
Frequently Asked Questions
Q: What doses were used in the retatrutide Phase 2 obesity trial? 1 mg, 4 mg, 8 mg, and 12 mg, all administered once weekly subcutaneously for 48 weeks, along with a placebo arm.
Q: Which dose showed the best weight reduction results in published research? The 12 mg dose, which produced 24.2% mean weight reduction at 48 weeks in the Phase 2 obesity trial compared to 2.1% with placebo.
Q: Did retatrutide outperform dulaglutide in clinical research? In the Phase 2 type 2 diabetes trial, retatrutide at all evaluated doses outperformed dulaglutide 1.5 mg on both weight reduction and HbA1c endpoints at 36 weeks. Dulaglutide is a GLP-1 receptor agonist with established efficacy in clinical use, making this comparison meaningful as a benchmark.
Q: Is this dosage information guidance for using retatrutide? No. This information documents dose ranges from published research for scientific reference only. Retatrutide is not approved for any therapeutic use and is sold by Palmetto Peptides for laboratory research only.
Peer-Reviewed Citations
- Jastreboff AM, et al. Retatrutide for Obesity -- Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide for type 2 diabetes. The Lancet. 2023;402(10401):529-544.
- Urva S, et al. A novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: phase 1b trial. The Lancet. 2022;399(10326):1869-1881.
- Sanyal AJ, et al. Retatrutide for MASLD: Phase 2a trial. Nature Medicine. 2024;30:2037-2048.
- Rajagopal S, et al. Meta-analysis of retatrutide RCTs. Baylor University Medical Center Proceedings. 2025;38(3):291-303.
Article prepared by the Palmetto Peptides Research Team. Last Updated: March 19, 2026
Retatrutide Research Peptide
Palmetto Peptides offers high-purity Retatrutide research peptide for qualified researchers. Each batch is third-party tested for purity and potency.